Eris Lifesciences Ltd

NSE: ERIS · BSE: 540596 · Pharmaceuticals & Biotechnology · 17 announcements

Share price: ₹1,258.90
Market cap: ₹17,466 Cr
Revenue (annual): ₹3,129 Cr
Net profit (annual): ₹619.5 Cr
P/E (TTM): 27.1×Sector 50.4×
Promoter holding: 54.14%+0.22% QoQ
FII holding: 5.76%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 3 Management Change 2 Annual General Meeting 2 Price Movement Clarification 1 Financial Results 1 Employee Stock Options 1 Debt & Borrowing 1 Annual Report 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

4 Aug 2026 10:43 IST BSE

Earnings Call

Eris Lifesciences Earnings Call Transcript: Key Takeaways

Eris Lifesciences Q1 FY27 showed 13% revenue growth, but shifting product mix toward lower-margin biologics and insulin is compressing gross margins. Management remains optimistic about GLP-1 uptake despite slow initial patient adoption.

Call: Guides 14% growth

Open call summary → Read the filing ↗

29 Jul 2026 18:31 IST NSE

Earnings Call

Eris Lifesciences Earnings Call Transcript: Key Takeaways

Eris reports steady 14% domestic growth but faces a gross margin contraction due to a higher mix of lower-margin biologics and insulin products.

Call: Guides 14% growth

Open call summary → Read the filing ↗

29 Jul 2026 13:16 IST NSE

Earnings Call

Eris Lifesciences Investor Presentation: Key Takeaways

Eris reports 13% YoY revenue growth in Q1 FY27, reaching ₹873 Cr, driven by a 14% increase in Domestic Branded Formulations (DBF) and strategic expansion into biologics and insulins.

Open call summary → Read the filing ↗